Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours 1

949 - Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)


20 Dec 2015


Gastrointestinal tumours 1


Eric van Cutsem


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


E. van Cutsem1, F. Ciardiello2, J. Seitz3, R.D. Hofheinz4, U. Verma5, R. Garcia-Carbonero6, A. Grothey7, A. Miriyala8, J. Kalmus9, J. Shapiro10, A. Falcone11, A. Zaniboni12

Author affiliations

  • 1 Digestive Oncology, University Hospitals Leuven and KU-Leuven, 3000 - Leuven/BE
  • 2 Department Of Experimental And Clinical Medicine And Surgery, Second University of Naples, 80131 - Naples/IT
  • 3 Department Of Digestive Oncology, Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille/FR
  • 4 Interdisziplinären Tumorzentrum, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim/DE
  • 5 Division Of Hematology And Oncology, University of Texas Southwestern Medical Center, Dallas/US
  • 6 Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla/ES
  • 7 Department Of Oncology, Mayo Clinic, 55905 - Rochester/US
  • 8 Global Pharmacovigilance And Risk Management, Bayer Pharma AG, Berlin/DE
  • 9 Global Clinical Development Oncology, Ophthalmology & Neurology, Bayer Pharma AG, Berlin/DE
  • 10 Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 11 Department Of Medical Oncology, University of Pisa, Pisa/IT
  • 12 Department Of Oncology, Fondazione Poliambulanza, Brescia/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 949


In the phase 3 CORRECT trial, regorafenib significantly improved overall survival vs placebo in patients with mCRC who progressed on standard therapies. CONSIGN (NCT01538680) was designed to provide regorafenib to patients with treatment-refractory mCRC who had no treatment alternatives, and to further characterize the safety of regorafenib (primary objective).


This prospective, single-arm study was carried out at 188 sites in 25 countries. Patients with mCRC who progressed after approved standard therapies and an ECOG PS 0─1 received regorafenib 160 mg QD for the first 3 weeks of each 4-week cycle. Treatment continued until progression, death, or unacceptable toxicity. The primary endpoint was safety. Progression-free survival (PFS) per investigator was the only efficacy variable assessed.


A total of 2872 patients were assigned from April 2012–December 2013; 2864 patients were treated. Median age was 62 yrs, ECOG PS 0/1 was 47%/53%, and 74% of patients had ≥3 prior regimens for metastatic disease. Median treatment duration was 2.5 months (range: 0–30); mean duration (SD) was 3.6 (3.8) months. The mean (SD) daily dose was 146 (19) mg. Treatment-emergent adverse events (TEAEs) led to dose reduction in 46% of patients and to treatment discontinuation in 25%. Regorafenib-related TEAEs (all grade) occurred in 91% of patients; the most common regorafenib-related grade ≥3 AEs are shown (Table). Treatment-emergent grade ≥3 laboratory toxicities included ALT (6%), AST (7%), and bilirubin (13%). One non-fatal case of severe drug-induced liver injury was identified by ongoing monitoring. Median PFS (95% CI) was 2.7 months (2.6─2.7).

Patients with drug-related TEAEs, % Regorafenib (N = 2864)
Grade ≥3* Hypertension HFSR Fatigue Diarrhea Hypophosphatemia 57 15 14 13 5 5
Serious 9
Leading to discontinuation 9

*In ≥5% of patients; graded by NCI-CTCAE v4.0. HFSR, hand–foot skin reaction.


In this large, prospective study of regorafenib in patients with treatment-refractory mCRC, TEAEs were consistent with the known safety profile of regorafenib. Median PFS was in the range of that reported in phase 3 trials.

Clinical trial identification



E. Van Cutsem: Corporate-sponsored research: Bayer HealthCare. F. Ciardiello: Advisory board: Roche, Merck Serono, Bayer, Sanofi, Astellas, Amgen, Lilly. J.-F. Seitz: Advisory Board: Bayer, Sanofi, Lilly. R.D. Hofheinz: Advisory Board: Bayer HealthCare Corporate-sponsored research: Bayer HealthCare. U. Verma: Advisory Board: Bayer. R. Garcia-Carbonero: uncompensated Advisory Board: Bayer, Roche, Amgen, Sanofi, Merck; Corporate-sponsored research: Bayer, Roche, Amgen, Merck. A. Grothey: Advisory Board: Genentech/Roche, Bayer, Sanofi, Bristol-Myers Squibb, Eli-Lilly, Boston Biomedicals, Amgen; Corporate-sponsored research: Genentech/Roche, Bayer, Pfizer, Eisai, Sanofi, Eli-Lilly, Boston Biomedicals. A. Miriyala, J. Kalmus: stock ownership: Bayer Other substantive relationships: Bayer employee. J. Shapiro: stock ownership: Bayer, Pfizer Other substantive relationships: Bayer Employee. A. Falcone: Advisory Board: Amgen, Bayer, Roche, Merck-Serono, Sanofi, Lilly; Corporate-sponsored research: Roche, Merck-Serono, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings